Antibody Technologies Rise to New Challenges

摘要

Periodically, we update the ABL readership with new information on the marketplace of monoclonal antibodies (MAbs) and the state-of-the-art of antibody technology. Last year's review (Das, R.; Morrow, J.K. Progress in antibody therapeutics. Am. Biotech. Lab. 2006, 24[8], 8-10) focused on the progress in therapeutic antibody development, noting that diagnostic antibodies have lagged behind in that they lack the financial driver of blockbuster drug possibilities. However, there are new demands and possibilities on both the commercial and technical sides of the equation that present opportunities for companies that profess expertise in antibody technologies or for those making efforts in earnest to move into this arena. Here, the authors provide a timely update of some of the noteworthy accomplishments for the past year in the field of recombinant antibody technology and point to some of the challenges for the future.